MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Vedolizumab (anti-α4β7-integrin)

产品活性：Vedolizumab (anti-α4β7-integrin) 是一种靶向 α4β7 整联蛋白 (integrin) 的人源化 IgG1 单克隆抗体，用于溃疡性结肠炎和克罗恩病的相关研究。

研究领域：Cytoskeleton

作用靶点：Integrin

In Vitro: Vedolizumab does not bind to the majority of memory CD4+ T lymphocytes (60%), neutrophils, and most monocytes. The highest level of vedolizumab binding is to a subset (25%) of human peripheral blood memory CD4+ T lymphocytes that include gut-homing interleukin 17 T-helper lymphocytes. Vedolizumab also binds to eosinophils at high levels, and to naive T-helper lymphocytes, naive and memory cytotoxic T lymphocytes, B lymphocytes, natural killer cells, and basophils at lower levels; vedolizumab binds to memory CD4+ T and B lymphocytes with subnanomolar potency (EC₅₀=0.3-0.4 nM). Vedolizumab selectively inhibits adhesion of α4β7-expressing cells to mucosal addressin cell adhesion molecule 1 (IC₅₀=0.02-0.06 g/mL) and fibronectin (IC₅₀=0.02 g/mL), but not vascular cell adhesion molecule 1.

In Vivo: Blockade of α4β7 receptors on T-lymphocytes has been shown to occur for several weeks after a single dose of vedolizumab. The drug concentration following the infusion has been shown to be dose related with a mean maximum concentration of 12.5 μg/mL in those receiving 0.5 mg/kg of vedolizumab and 52.0 μg/mL in those receiving 2 mg/kg. The serum half-life of these two doses is 9-12 days respectively and saturation of α4β7 receptors on T-lymphocytes is >90% at both 4-6 weeks following infusion. In a dose ranging study, the serum drug concentrations increase with increasing dose and when regular induction infusions are used (on day 1, 15, 29 and 85), the serum half-life is between 15 and 22 days across all groups.

相关产品：Cilengitide  |  CWHM-12  |  Cyclo(-RGDfK)  |  MK-0429  |  GLPG0187  |  E7820  |  iRGD peptide  |  ATN-161 trifluoroacetate salt  |  Lifitegrast  |  Cucurbitacin B  |  Arg-Gly-Asp-Ser  |  A-205804  |  ILK-IN-3  |  Eptifibatide  |  Pyrintegrin  |  αvβ1 integrin-IN-1 TFA  |  RGD Trifluoroacetate  |  Leukadherin-1  |  OSU-T315  |  Natalizumab  |  RGD peptide (GRGDNP) (TFA)  |  Vedolizumab  |  Firategrast  |  Tetrac  |  Carotegrast methyl  |  Tirofiban  |  BIO5192 hydrate  |  Zaurategrast

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。